NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 27, 2017 to file lead plaintiff applications in a securities class action lawsuit against Vitamin Shoppe, Inc. (NYSE:VSI), if they purchased the Company’s shares between the expanded period of March 1, 2017 and August 8, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Vitamin Shoppe investors should visit us at https://www.claimsfiler.com/cases/nasdaq-vsi or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Vitamin Shoppe and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 1, 2017, Vitamin Shoppe announced that it expected to deliver “[f]ully diluted earnings per share in the range of $1.95 - $2.20” during fiscal year 2017. Subsequently, on May 10, 2017, the Company slashed FY17 guidance by more than 45% and then on August 9, 2017, revealed it was taking a goodwill impairment charge of $168 million and as a result, a GAAP loss per share of $6.73 in 2Q17.
On this news, the price of Vitamin Shoppe’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Bank of America's $72.5M Epstein Settlement: What You Need to Know
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



